Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CSER: The Use of Sequencing to Guide the Care of Cancer Patients

ABSTRACT: CSER: The Use of Sequencing to Guide the Care of Cancer Patients

PROVIDER: PRJNA312991 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Homo sapiens

Project description:CSER: The Use of Sequencing to Guide the Care of Cancer Patients

| PRJNA312992 | ENA

CSER: Incorporation of Genomic Sequencing into Pediatric Cancer Care

Project description:CSER: Incorporation of Genomic Sequencing into Pediatric Cancer Care

| PRJNA489747 | ENA

CSER: Incorporation of Genomic Sequencing into Pediatric Cancer Care

Project description:CSER: Incorporation of Genomic Sequencing into Pediatric Cancer Care

| PRJNA489749 | ENA

CSER: Incorporating Genomics into the Clinical Care of Diverse NYC Children (NYCKidSeq)

Project description:CSER: Incorporating Genomics into the Clinical Care of Diverse NYC Children (NYCKidSeq)

| PRJNA698013 | ENA

CSER: Incorporating Genomics into the Clinical Care of Diverse NYC Children (NYCKidSeq)

Project description:CSER: Incorporating Genomics into the Clinical Care of Diverse NYC Children (NYCKidSeq)

| PRJNA698014 | ENA

Transposon-encoded nucleases use guide RNAs to selfishly bias their inheritance

Project description:Transposon-encoded nucleases use guide RNAs to selfishly bias their inheritance

| PRJNA925099 | ENA

A proteomic survival predictor for COVID-19 patients in intensive care

Project description:Global healthcare systems are challenged by the COVID-19 pandemic. There is a need to optimize allocation of treatment and resources in intensive care, as clinically established risk assessments such as SOFA and APACHE II scores show only limited performance for predicting the survival of severely ill COVID-19 patients. Comprehensively capturing the host physiology, we speculated that proteomics in combination with new data-driven analysis strategies could produce a new generation of prognostic discriminators. We studied two independent cohorts of patients with severe COVID-19 who required intensive care and invasive mechanical ventilation. SOFA score, Charlson comorbidity index and APACHE II score were poor predictors of survival. Instead, using plasma proteomes quantifying 302 plasma protein groups at 387 timepoints in 57 critically ill patients on invasive mechanical ventilation, we found 14 proteins that showed trajectories different between survivors and non-survivors. A proteomic predictor trained on single samples obtained at the first time point at maximum treatment level (i.e. WHO grade 7) and weeks before the outcome, achieved accurate classification of survivors (AUROC 0.81, n=49). We tested the established predictor on an independent validation cohort (AUROC of 1.0, n=24). The majority of proteins with high relevance in the prediction model belong to the coagulation system and complement cascade. Our study demonstrates that predictors derived from plasma protein levels have the potential to substantially outperform current prognostic markers in intensive care.

2022-03-03 | PXD029009 | Pride

Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases can be used to guide therapy

Project description:Purpose: Colorectal cancer (CRC) patients with peritoneal metastases (CRPM) have limited treatment options and the lowest CRC survival rates. We aimed to determine whether organoid testing could help guide precision treatment for CRPM patients, as the clinical utility of prospective, functional drug screening including non-standard agents is unknown. Experimental Design: CRPM organoids (peritonoids) isolated from patients underwent parallel next-generation sequencing and medium-throughput drug panel testing ex vivo to identify specific drug sensitivities for each patient. We measured the utility of such a service including: success of peritonoid generation, time to cultivate peritonoids, reproducibility of the medium-throughput drug testing, and documented changes to clinical therapy as a result of the testing. Results: Peritonoids were successfully generated and validated from 68% (19/28) of patients undergoing standard care. Genomic and drug profiling was completed within 8 weeks and a formal report ranking drug sensitivities was provided to the medical oncology team upon failure of standard care treatment. This resulted in a treatment change for 2 patients, one of whom had a partial response despite previously progressing on multiple rounds of standard care chemotherapy. The barrier to implementing this technology in Australia is the need for drug access and funding for off-label indications. Conclusions: Our approach is feasible, reproducible and can guide novel therapeutic choices in this poor prognosis cohort, where new treatment options are urgently needed. This platform is relevant to many solid organ malignancies.

2020-05-31 | GSE147971 | GEO

RockDove Parental Care

Project description:RockDove Parental Care

| PRJEB28684 | ENA

EJP CARE - SVA

Project description:EJP CARE - SVA

| PRJEB48129 | ENA